|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
(+ 0 more)
144 a.a.
|
 |
|
|
|
|
|
|
|
(+ 0 more)
12 a.a.
|
 |
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
|
PDB id:
|
 |
|
 |
| Name: |
 |
Immune system
|
 |
|
Title:
|
 |
Complex between baff and a br3 derived peptide presented in a beta-hairpin scaffold
|
|
Structure:
|
 |
Tumor necrosis factor ligand superfamily member 13b. Chain: a, b, c, d, e, f. Fragment: tnf domain. Synonym: tnf-and apol- related leukocyte expressed ligand 1, tall-1, b lymphocyte stimulator, blys, b cell- activating factor, baff, dendritic cell- derived tnf-like molecule. Engineered: yes.
|
|
Source:
|
 |
Homo sapiens. Human. Organism_taxid: 9606. Gene: baff. Expressed in: escherichia coli bl21(de3). Expression_system_taxid: 469008. Synthetic: yes. Other_details: this peptide was chemically synthesized.
|
|
Biol. unit:
|
 |
Hexamer (from
)
|
|
Resolution:
|
 |
|
3.00Å
|
R-factor:
|
0.220
|
R-free:
|
0.286
|
|
|
Authors:
|
 |
N.C.Gordon,B.Pan,S.G.Hymowitz,J.P.Yin,R.F.Kelley, A.G.Cochran,M.Yan,V.M.Dixit,W.J.Fairbrother,M.A.Starovasnik
|
Key ref:
|
 |
N.C.Gordon
et al.
(2003).
BAFF/BLyS receptor 3 comprises a minimal TNF receptor-like module that encodes a highly focused ligand-binding site.
Biochemistry,
42,
5977-5983.
PubMed id:
DOI:
|
 |
|
Date:
|
 |
|
19-Mar-03
|
Release date:
|
27-May-03
|
|
|
|
|
|
PROCHECK
|
|
|
|
|
Headers
|
 |
|
|
References
|
|
|
|
|
|
|
|
 |
|
 |
|
 |
|
|
Gene Ontology (GO) functional annotation
|
|
|
|
 |
 |
 |
|
 |
 |
 |
 |
|
 |
|
Cellular component
|
membrane
|
1 term
|
 |
|
Biological process
|
immune response
|
1 term
|
 |
|
Biochemical function
|
tumor necrosis factor receptor binding
|
1 term
|
 |
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
DOI no:
|
Biochemistry
42:5977-5983
(2003)
|
|
PubMed id:
|
|
|
|
|
| |
|
BAFF/BLyS receptor 3 comprises a minimal TNF receptor-like module that encodes a highly focused ligand-binding site.
|
|
N.C.Gordon,
B.Pan,
S.G.Hymowitz,
J.Yin,
R.F.Kelley,
A.G.Cochran,
M.Yan,
V.M.Dixit,
W.J.Fairbrother,
M.A.Starovasnik.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
BAFF/BLyS, a member of the tumor necrosis family (TNF) superfamily of ligands,
is a crucial survival factor for B cells. BAFF binds three receptors, TACI,
BCMA, and BR3, with signaling through BR3 being essential for promoting B cell
function. Typical TNF receptor (TNFR) family members bind their cognate ligands
through interactions with two cysteine-rich domains (CRDs). However, the
extracellular domain (ECD) of BR3 consists of only a partial CRD, with cysteine
spacing distinct from other modules described previously. Herein, we report the
solution structure of the BR3 ECD. A core region of only 19 residues adopts a
stable structure in solution. The BR3 fold is analogous to the first half of a
canonical TNFR CRD but is stabilized by an additional noncanonical disulfide
bond. BAFF-binding determinants were identified by shotgun alanine-scanning
mutagenesis of the BR3 ECD expressed on phage. Several of the key BAFF-binding
residues are presented from a beta-turn that we have shown previously to be
sufficient for ligand binding when transferred to a structured beta-hairpin
scaffold [Kayagaki, N., Yan, M., Seshasayee, D., Wang, H., Lee, W., French, D.
M., Grewal, I. S., Cochran, A. G., Gordon, N. C., Yin, J., Starovasnik, M. A,
and Dixit, V. M. (2002) Immunity 10, 515-524]. Outside of the turn, mutagenesis
identifies additional hydrophobic contacts that enhance the BAFF-BR3
interaction. The crystal structure of the minimal hairpin peptide, bhpBR3, in
complex with BAFF reveals intimate packing of the six-residue BR3 turn into a
cavity on the ligand surface. Thus, BR3 binds BAFF through a highly focused
interaction site, unprecedented in the TNFR family.
|
|
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
E.Margolles-Clark,
N.S.Kenyon,
C.Ricordi,
and
P.Buchwald
(2010).
Effective and specific inhibition of the CD40-CD154 costimulatory interaction by a naphthalenesulphonic acid derivative.
|
| |
Chem Biol Drug Des, 76,
305-313.
|
 |
|
|
|
|
 |
W.Hugo,
F.Song,
Z.Aung,
S.K.Ng,
and
W.K.Sung
(2010).
SLiM on Diet: finding short linear motifs on domain interaction interfaces in Protein Data Bank.
|
| |
Bioinformatics, 26,
1036-1042.
|
 |
|
|
|
|
 |
L.S.Treml,
W.J.Quinn,
J.F.Treml,
J.L.Scholz,
and
M.P.Cancro
(2008).
Manipulating B cell homeostasis: a key component in the advancement of targeted strategies.
|
| |
Arch Immunol Ther Exp (Warsz), 56,
153-164.
|
 |
|
|
|
|
 |
M.R.Schmidt,
M.C.Appel,
L.J.Giassi,
D.L.Greiner,
L.D.Shultz,
and
R.T.Woodland
(2008).
Human BLyS facilitates engraftment of human PBL derived B cells in immunodeficient mice.
|
| |
PLoS ONE, 3,
e3192.
|
 |
|
|
|
|
 |
F.K.Chan
(2007).
Three is better than one: pre-ligand receptor assembly in the regulation of TNF receptor signaling.
|
| |
Cytokine, 37,
101-107.
|
 |
|
|
|
|
 |
G.Fuh
(2007).
Synthetic antibodies as therapeutics.
|
| |
Expert Opin Biol Ther, 7,
73-87.
|
 |
|
|
|
|
 |
S.S.Sidhu,
and
A.A.Kossiakoff
(2007).
Exploring and designing protein function with restricted diversity.
|
| |
Curr Opin Chem Biol, 11,
347-354.
|
 |
|
|
|
|
 |
C.Bossen,
and
P.Schneider
(2006).
BAFF, APRIL and their receptors: structure, function and signaling.
|
| |
Semin Immunol, 18,
263-275.
|
 |
|
|
|
|
 |
L.S.Treml,
J.E.Crowley,
and
M.P.Cancro
(2006).
BLyS receptor signatures resolve homeostatically independent compartments among naïve and antigen-experienced B cells.
|
| |
Semin Immunol, 18,
297-304.
|
 |
|
|
|
|
 |
M.P.Cancro
(2006).
The BLyS/BAFF family of ligands and receptors: key targets in the therapy and understanding of autoimmunity.
|
| |
Ann Rheum Dis, 65,
iii34-iii36.
|
 |
|
|
|
|
 |
S.R.Dillon,
J.A.Gross,
S.M.Ansell,
and
A.J.Novak
(2006).
An APRIL to remember: novel TNF ligands as therapeutic targets.
|
| |
Nat Rev Drug Discov, 5,
235-246.
|
 |
|
|
|
|
 |
S.G.Hymowitz,
and
A.Ashkenazi
(2005).
Toward small-molecule agonists of TNF receptors.
|
| |
Nat Chem Biol, 1,
353-354.
|
 |
|
|
|
|
 |
S.G.Hymowitz,
D.R.Patel,
H.J.Wallweber,
S.Runyon,
M.Yan,
J.Yin,
S.K.Shriver,
N.C.Gordon,
B.Pan,
N.J.Skelton,
R.F.Kelley,
and
M.A.Starovasnik
(2005).
Structures of APRIL-receptor complexes: like BCMA, TACI employs only a single cysteine-rich domain for high affinity ligand binding.
|
| |
J Biol Chem, 280,
7218-7227.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
D.R.Patel,
H.J.Wallweber,
J.Yin,
S.K.Shriver,
S.A.Marsters,
N.C.Gordon,
M.A.Starovasnik,
and
R.F.Kelley
(2004).
Engineering an APRIL-specific B cell maturation antigen.
|
| |
J Biol Chem, 279,
16727-16735.
|
 |
|
|
|
|
 |
G.Zhang
(2004).
Tumor necrosis factor family ligand-receptor binding.
|
| |
Curr Opin Struct Biol, 14,
154-160.
|
 |
|
|
|
|
 |
M.P.Cancro
(2004).
The BLyS family of ligands and receptors: an archetype for niche-specific homeostatic regulation.
|
| |
Immunol Rev, 202,
237-249.
|
 |
|
|
|
|
 |
A.L.Gavin,
D.Aït-Azzouzene,
C.F.Ware,
and
D.Nemazee
(2003).
DeltaBAFF, an alternate splice isoform that regulates receptor binding and biopresentation of the B cell survival cytokine, BAFF.
|
| |
J Biol Chem, 278,
38220-38228.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
codes are
shown on the right.
|
|